转甲状腺素蛋白淀粉样心肌病骨闪烁显像右心室摄取临床与预后意义
本研究纳入1422例ATTR-CM患者,基于SPECT将右心室摄取分为局灶性与弥漫性。中位随访34个月,494例死亡,弥漫性右心室摄取与更高全因死亡率相关(77.9% vs 22.1%,P<0.001),且为独立预后预测因子(HR 1.60,95%CI 1.26-2.04,P<0.001)。
要点
- SPECT示右心室弥漫性摄取患者全因死亡率显著高于局灶性摄取。
- 弥漫性右心室摄取是ATTR-CM诊断时独立的全因死亡预测因子。
- Perugini分级与生存无显著关联,右心室摄取模式提供额外预后信息。
核心结论
- SPECT骨闪烁显像示右心室弥漫性摄取与ATTR-CM患者不良结局相关,是诊断时的独立预后标志物。
研究设计与样本
- 连续纳入来自国家淀粉样变性中心及4个意大利中心的ATTR-CM患者,均行全身平面及心脏SPECT骨闪烁显像,共1422例。
主要发现
- 中位随访34个月(IQR 21-50),494例死亡。
- 弥漫性右心室摄取(n=936)与局灶性(n=486)相比全因死亡率更高(77.9% vs 22.1%,P<0.001)。
- Perugini 2级与3级间生存无差异(P=0.27)。
- 多变量调整后弥漫性右心室摄取仍为全因死亡的独立预测因子(HR 1.60,95%CI 1.26-2.04,P<0.001)。
- 弥漫性右心室摄取的预后价值在各NAC分期及野生型与遗传型ATTR-CM中均维持(P<0.001和P=0.02)。
关键数值与推荐
- 右心室摄取按SPECT定义:局灶性为仅右心室游离壁基底段,弥漫性为超出基底段。
- 心脏摄取按Perugini分级:0无,1轻度低于骨,2中度等于骨,3高度大于骨。
临床怎么用
- 在ATTR-CM诊断时,应评估SPECT右心室摄取模式(局灶 vs 弥漫)以辅助风险分层。
- 弥漫性右心室摄取提示预后较差,可考虑加强随访与治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amyloid burden and be associated with outcome. METHODS: Consecutive patients with ATTR-CM who underwent diagnostic bone tracer scintigraphy with acquisition of whole-body planar and cardiac single-photon emission computed tomography (SPECT) images from the National Amyloidosis Centre and 4 Italian centers were included. Cardiac uptake was defined according to the Perugini classification: 0=absent cardiac uptake; 1=mild uptake less than bone; 2=moderate uptake equal to bone; and 3=high uptake greater than bone. Extent of right ventricular (RV) uptake was defined as focal (basal segment of the RV free wall only) or diffuse (extending beyond basal segment) on the basis of SPECT imaging. The primary outcome was all-cause mortality. RESULTS: Among 1422 patients with ATTR-CM, RV uptake accompanying left ventricular uptake was identified by SPECT imaging in 100% of cases at diagnosis. Median follow-up in the whole cohort was 34 months (interquartile range, 21 to 50 months), and 494 patients died. By Kaplan-Meier analysis, diffuse RV uptake on SPECT imaging (n=936) was associated with higher all-cause mortality compared with focal (n=486) RV uptake (77.9% versus 22.1%; P<0.001), whereas Perugini grade was not associated with survival (P=0.27 in grade 2 versus grade 3). On multivariable analysis, after adjustment for age at diagnosis (hazard ratio [HR], 1.03 [95% CI, 1.02-1.04]; P<0.001), presence of the p.(V142I) TTR variant (HR, 1.42 [95% CI, 1.20-1.81]; P=0.004), National Amyloidosis Centre stage (each category, P<0.001), stroke volume index (HR, 0.99 [95% CI, 0.97-0.99]; P=0.043), E/e' (HR, 1.02 [95% CI, 1.007-1.03]; P=0.004), right atrial area index (HR, 1.05 [95% CI, 1.02-1.08]; P=0.001), and left ventricular global longitudinal strain (HR, 1.06 [95% CI, 1.03-1.09]; P<0.001), diffuse RV uptake on SPECT imaging (HR, 1.60 [95% CI, 1.26-2.04]; P<0.001) remained an independent predictor of all-cause mortality. The prognostic value of diffuse RV uptake was maintained across each National Amyloidosis Centre stage and in both wild-type and hereditary ATTR-CM (P<0.001 and P=0.02, respectively). CONCLUSIONS: Diffuse RV uptake of bone tracer on SPECT imaging is associated with poor outcomes in patients with ATTR-CM and is an independent prognostic marker at diagnosis.
引用
- Porcari A, Fontana M, Canepa M, et al. Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy. Circulation. 2024. PMID: 38328945. doi:10.1161/CIRCULATIONAHA.123.066524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。